VOR
Vor Biopharma Inc.
Company Overview
| Mkt Cap | $212.95M | Price | $14.49 |
| Volume | 2.88M | Change | -3.53% |
| P/E Ratio | -0.3 | Open | $15.18 |
| Revenue | -- | Prev Close | $15.02 |
| Net Income | $-696.0M | 52W Range | $4.60 - $65.80 |
| Div Yield | N/A | Target | $36.14 |
| Overall | 45 | Value | 60 |
| Quality | 15 | Technical | 60 |
No chart data available
About Vor Biopharma Inc.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest News
Vor Biopharma shareholders back directors and governance measures
Vor Bio gains boost from telitacicept IgA nephropathy approval
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VOR | $14.49 | -3.5% | 2.88M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |